VVOS (Vivos Therapeutics) Marketable Securities: $0.00 Mil (As of Mar. 2026)


VVOS Vivos Therapeutics Inc VVOS
41 GF Score
Price $0.48
GF Value $1.15
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vivos Therapeutics Marketable Securities?

Vivos Therapeutics VVOS +6.47% 41 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Vivos Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Vivos Therapeutics  (NAS:VVOS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Vivos Therapeutics Marketable Securities Related Terms

Vivos Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Vivos Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Therapeutics Marketable Securities Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Vivos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VVOS
41GF Score
Vivos Therapeutics Inc VVOS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivos Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Vivos Therapeutics (VVOS) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vivos Therapeutics and its competitors.
Is Vivos Therapeutics' Marketable Securities too high?
Vivos Therapeutics' current Marketable Securities is $0.00 Mil. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Marketable Securities compare to XAIR and TNON?
Vivos Therapeutics' Marketable Securities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Vivos Therapeutics and its competitors. Vivos Therapeutics's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.48 — trading 58.4% below its estimated fair value. The current Marketable Securities is $0.00 Mil. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivos Therapeutics (VVOS) Overvalued in 2026?

Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued. The current stock price of $0.48 is trading 58.4% below its estimated GF Value™ of $1.15. GuruFocus considers Vivos Therapeutics to be Possible Value Trap.

Key valuation signals for VVOS:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $1.15 vs. price of $0.48 (58.4% below fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vivos Therapeutics Business Description

Address 7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score

Get the complete analysis for VVOS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price
$1.15
GF Value